Clinical Trials Browser

Interventional × Rosiglitazone × Clear all

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Phase 2 Completed

Liposarcoma, Sarcoma

NCT01019356 2022-01-20

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

Phase NA Completed

Polycystic Ovary Syndrome

NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Phase 2 Terminated

1 enrolled 4 charts

Pituitary Neoplasms, Central Nervous System Neoplasms

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Phase 2 Terminated

2 enrolled 5 charts

Pituitary ACTH Hypersecretion

NCT01287598 2019-07-10

BAY73-4506 Probe Substrate Study

Phase 1 Completed

Neoplasms

NCT00640224 2017-11-17

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

Phase 4 Completed

65 enrolled 28 charts

Polycystic Ovary Syndrome

NCT03309319 2017-10-13

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Phase NA Unknown

Pituitary Neoplasms

NCT00428090 2017-05-19

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

Phase 3 Completed

862 enrolled 36 charts

Alzheimer Disease, Lymphoma, Follicular

NCT00933309 2016-02-19

The Impact of Obesity and Obesity Treatments on Breast Cancer

Phase 1 Completed

Breast Neoplasms, Obesity

NCT00178841 2016-02-17

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

Phase 2 Completed

4 enrolled 5 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01209143 2015-06-29

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Phase 1 Completed

52 enrolled 8 charts

Solid Cancers

NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Phase 1 Completed

EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

NCT00084578 2013-07-15

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Phase NA Withdrawn

Urinary Bladder Neoplasms

NCT00182052 2013-05-23

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Phase 2 Completed

Leukoplakia, Oral